This is the program for the 2010 Joint Statistical Meetings in Vancouver, British Columbia.

Activity Details

256 Mon, 8/2/2010, 2:00 PM - 3:50 PM CC-Exhibit Hall A (West)
Contributed Oral Poster Presentations: Biopharmaceutical Section — Contributed Poster Presentations
Biopharmaceutical Section
Chair(s): Peiyong (Annie) Qu, University of Illinois at Urbana-Champaign
01: Validation of a Monte-Carlo Markov Model for Schizophrenia Alice Dragomir, Université de Montréal ; Jean-Francois Angers, Université de Montréal ; Jean-Eric Tarride, McMaster University ; Syvie Perreault, Université de Montréal
02: WITHDRAWN: Functional Mixed-Effects Modeling of Electroencephalographic (EEG) Data — Shubhankar Ray, Merck & Co., Inc.
03: Statistical Evaluation of Nonprofile Analyses for In Vitro Bioequivalence Jen-pei Liu, National Taiwan University
05: Power and Robustness of Nonparametric Covariate Adjustment Methods for Ordinal Data — Muhtarjan Osman, North Carolina State University ; Wei Tian, Inspire Pharmaceuticals
06: A Multiple Imputation Approach for Estimating Rank Correlation with Left-Censored Data — John M. Williamson, CDC ; Sara B. Crawford, Valparaiso University ; Hung-Mo Lin, Mount Sinai School of Medicine
07: Establishing Sample Size in Clinical Trials Having Multiple Hypotheses Alan Barry Davis, Pharmanet Development Group, Inc. ; Mary M. Poole, Pharmanet Development Group, Inc. ; Young Kim, Pharmanet Development Group, Inc.
08: Correcting an Incorrect Statistical Practice in Pharmacokinetics and Related Fields Jingyuan Wang, Millennium Pharmaceuticals, Inc.
09: WITHDRAWN: Statistics in Bioprocess Development — Priya Kulkarni, Genentech ; Dan Coleman, Genentech
10: Longitudinal Methods for Analysis of Tumor Burden Data Ritwik Sinha, Bristol-Myers Squibb ; Aparna B. Anderson, Bristol-Myers Squibb
11: Statistical Considerations on Validating Microarray Platform in Clinical Development Guang (Gary) Chen, Merck & Co., Inc. ; Christopher Ramsborg, Merck & Co., Inc. ; Yue Wang, Merck & Co., Inc. ; Miho Kibukawa, Merck & Co., Inc. ; Joel A. Klappenbach, Merck & Co., Inc.
12: Harmonic Regression Analysis of Periodic Time Series Data from Clinical Trials Michael T. Gaffney , Pfizer Inc. ; Martin O. Carlsson, Pfizer Inc. ; Kelly H. Zou, Pfizer Inc.
13: Adjusted Cumulative Distribution Function and Effect Size Methods for Stratified Two-Sample Comparisons — Kelly H. Zou, Pfizer Inc. ; Martin O. Carlsson, Pfizer Inc. ; Ching-Ray Yu, Pfizer Inc.
14: Characterizing the Mutation Pathway for Integrase Inhibitor Jing Zhao, Merck Research Laboratories
15: Calculating an Exact p-Value for a Noninferiority Test on Matched Pair Data Jennifer E. Hamer-Maansson, AstraZeneca
16: Analysis of Overall Survival When Length of Treatment and Treatment Switching Are Time-Dependent Outcomes of Oncology Trials Jinwei Yuan, ICON Clinical Research
17: WITHDRAWN: Hierarchical Poisson Regression Model with Application to Efficacy Data of ZOSTAVAXTM for Evaluating Vaccine Waning Effect — Shu-Chih Su, Merck & Co., Inc.
18: Definition of a Responder in Clinical Trials for Alcohol Dependence Yun-Fei Chen, Eli Lilly and Company ; Xiwen Ma, University of Wisconsin-Madison
19: WITHDRAWN: Bayesian Methods in Combination Drug Studies: A Performance Analysis — Peiqi Zhai, Southern Methodist University
20: Semiparametric AUC Model with Placement Values Lin Zhang, Quintiles ; Jack Tubbs, Baylor University
21: Transfer of Methods Supporting Biologics and Vaccines Rong Liu, Merck & Co., Inc. ; Timothy Schofield, GlaxoSmithKline ; Jason Liao, Merck Research Laboratories
22: A Simulation Study to Evaluate Dose-Response in Dose-Titration Clinical Trials: A Dynamic Linear Mixed Effect (DLME) Modeling Approach Xu Steven Xu, Johnson & Johnson ; Min Yuan, Fudan University, China ; Julia Wang, Johnson & Johnson ; Partha Nandy, Johnson & Johnson
23: WITHDRAWN: Comparison of Imputation Methods for the Delayed Start Design in Studies of Alzheimer's Disease — Kathryn Dawson, PPD, Inc.
24: Survival Methods for Modeling the Time to Drop-Out in Pain Studies Tilda Chuang, Abbott Laboratories ; Wei Liu, Abbott Laboratories ; Sandeep Dutta, Abbott Laboratories
25: In Vitro Drug Combination Analysis in Excel: A Case Study in HIV Karen Chiswell, GlaxoSmithKline ; Katja Sabine Remlinger, GlaxoSmithKline ; Mark Underwood, GlaxoSmithKline
26: Evaluating Endpoint Determination and Approaches for Handling Missing Data in Pain Trials — Lindsey Lian, PPD, Inc. ; Benjamin Luke Peterson, PPD, Inc.
27: Analysis of Statistical Tests to Compare Cumulative Proportion of Responders for Pain Data in Clinical Trials Song Wang, PPD, Inc.
28: Comparison of Longitudinal Analyses of Binary Outcome Data: Marginal Models vs. Generalized Linear Mixed Models Qian Dong, Merck Sharp & Dohme Corp.
29: Recent Development in Exact Inference for Categorical Data — Dar Shong Hwang, B.R.S.I. ; James Lee, Daiichi Sankyo Pharma Development
30: The Use of Contrast-Enhancing Lesions to Predict Imminent Relapse: Validating Cutter's Rule Charity Johanna Morgan, The University of Alabama at Birmingham ; Ashutosh Ranjan, The University of Alabama at Birmingham ; Gary Cutter, University of Alabama at Birmingham
31: Competing Risks Methods in Safety Analysis of Oncology Clinical Trials — Sofia Paul, Novartis Pharmaceuticals Corporation ; Bingqing Zhou, The University of North Carolina at Chapel Hill ; Samit Hirawat, Novartis Pharma ; Glen Laird, Novartis Pharmaceuticals Corporation
32: Identifying Treatment Responsive Trajectory Classes in a Depression Trial: An Alternative Statistical Approach Maggie Kuchibhatla, Duke University Medical Center ; Gerda Fillenbaum, DUMC
33: A Bootstrap Approach to Estimating Antibody Levels in Case of Non-Normal Data Roger Maansson, Merck & Co., Inc.
34: Implementation of EWOC (Escalation With Overdose Controls) Adaptive Dose-Finding Design in a Phase IIA Clinical Trial Catherine Bresee, Oschin Comprehensive Cancer Institute ; Amir Steinberg, Oschin Comprehensive Cancer Institute ; Jeremy Rudnick, Oschin Comprehensive Cancer Institute ; Andre Rogatko, Oschin Comprehensive Cancer Institute
35: Analyzing Correlated Binary Data: Examples from Aquaculture Studies — Kyunghee Kim Song, FDA/CDRH ; Todd Blessinger, HHS/FDA/CVM
36: Comparison of Power for ANCOVA Models Based on Central Tendency versus Nonparametric Analysis of Cumulative Responders for Clinical Trials with Continuous Response Endpoints Kevin L. Lawson, PPD, Inc.
37: Comparisons of Methods in Phase I Dose-Escalation Clinical Trial Designs Liping Huang, Bayer HealthCare Pharmaceuticals
38: A General Framework of Adaptive Designs for Early-Phase Oncology Clinical Trials Lixin Lang, Bristol-Myers Squibb ; Ralph Raymond, Bristol-Myers Squibb
39: A Model for Multilevel Clustered Data with Informative Cluster Size Using Poisson Distribution Ana-Maria Iosif, University of California, Davis ; Allan Sampson, University of Pittsburgh
40: Using Pilot Study for Clinical Study Planning Hongbin Gu, The University of North Carolina at Chapel Hill ; Xiaofei Wang, Duke University

2010 JSM Online Program Home

For information, contact or phone (888) 231-3473.

If you have questions about the Continuing Education program, please contact the Education Department.